Table 1.
Patient, tumor and treatment characteristics.
| n | % | |
|---|---|---|
| Patients | 93 | 100 |
| Gender | ||
| Female | 33 | 35.5 |
| Male | 60 | 64.5 |
| Median age (range years) | 61 (23–77) | |
| KPS | ||
| 70 | 6 | 6.4 |
| 80 | 20 | 21.6 |
| 90–100 | 67 | 72 |
| Histology | ||
| Glioblastoma | 93 | 100 |
| Tumor molecular profile | ||
| IDH wild type | 93 | 100 |
| MGMT methylated | 53 | 57 |
| MGMT unmethylated | 40 | 43 |
| Treatments | ||
| Surgical resection | 93 | 100 |
| HFRT | 93 | 100 |
| Total doses/dose per fraction Gy | ||
| CTV1/PTV1 | 60/4 | 100 |
| CTV2/PTV2 | 42/2.8 | 100 |
| Number of fractions | 15 | 100 |
| Median duration weeks (range weeks) | 3 (2.6–4.1) | |
| Chemotheraphy | ||
| Concomitant temozolomide | 91 | 97.8 |
| Never started concomitant temozolomide | 2 | 2.2 |
| Adjuvant temozolomide | 91 | 97.8 |
| Median number of cycles (range) | 6 (1–12) | |
| Never started adjuvant temozolomide | 2 | 2.2 |
KPS—Karnofsky performance scale; IDH1—Isocitrate dehydrogenase; MGMT—O-6 methylguanine-DNA methyltransferase; HFRT—hypofractionated radiation therapy; CTV—clinical target volume.